Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

J&J Raises Underlying Guidance After Strong Q4, but Legal Risks Linger

Published 01/22/2020, 06:37 AM
Updated 01/22/2020, 07:12 AM
© Reuters.  J&J Earnings Beat, Revenue Misses In Q4

© Reuters. J&J Earnings Beat, Revenue Misses In Q4

Investing.com - Johnson & Johnson (NYSE:JNJ) raised its guidance for underlying earnings and revenue after a strong fourth quarter on Wednesday but was unable to stop reported earnings slumping due to costs related to opioid- and talc-related lawsuits.

The company announced fourth-quarter adjusted earnings of $1.88 a share for the quarter, 1c ahead of forecasts, but reported earnings tumbled by 54% to only 66c. Revenue also fell short of forecasts slightly at $20.75 billion.

EPS were down from $1.97 a year ago, while revenue edged up from $20.39 billion.

The company now expects underlying earnings of a range between $8.62 and $8.67 for 2019, up from a range of $8.53-$8.63 previously. Chief executive Alex Gorsky pointed to "underlying growth in Pharmaceuticals and Medical Devices, as well as continued optimization in our Consumer business" as the reasons.

However, J&J warned that it can't give forecasts for GAAP line items such as net profit because it is "unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort."

The outlook still threatens to be a drag on its performance in 2020, according to Investing.com analyst Haris Anwar.

"It’s tough for investors to focus on J&J’s fundamentals when the company is facing thousands of lawsuits in the U.S. over product safety and marketing practices for a range of products including baby powder and opioids," Anwar said. "In addition to these legal issues, there is a good amount of political uncertainty related to the U.S. presidential election that makes healthcare stocks a risky trade in 2020."

J&J (NYSE:JNJ) stock hit a new record high on Tuesday and finished up 2.3% for the year to date.

J&J follows other major Healthcare sector earnings this month

On October 31, 2019, Novocure Ltd reported third quarter EPS of $0.02 on revenue of $92.06M, was in comparison with a forecasts for EPS of $-0.04 on revenue of $86.94M.

ABIOMED earnings beat analysts' expectations on January 13, with third quarter EPS of $1.09 on revenue of $221.6M. Investing.com analysts forecast EPS of $1.07 on revenue of $226.67M

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.